title: Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas.
abstract: Peripheral T- and NK-cell lymphomas (PT/NKCLs) are relatively rare, and few studies have validated the International Prognostic Index (IPI) for PT/NKCLs in prospective clinical trials. Histopathological specimens from 136 patients, enrolled in six prospective multicenter trials of doxorubicin-containing regimens, with PT/NKCLs were reviewed by six hematopathologists following the WHO classification. This combined analysis demonstrated that the IPI was not predictive of prognosis for patients with PT/NKCLs as previously shown by GELA. In a univariate analysis, low total serum protein (TP) and albumin levels, gastrointestinal tract involvement, and histologic subtype (extranodal NK/T-cell lymphoma, nasal type, and peripheral T-cell lymphoma, unspecified) were significantly associated with reduced survival. In a multivariate analysis, TP (p = 0.004) and histologic subtype (p = 0.024) remained significant. We discuss the need to establish the importance and meaning of TP and to develop new strategies for patients with PT/NKCLs allowing for TP, especially with worse histologic subtypes.
authors.affiliation: Hematology Division, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. takawata@ncc.go.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Watanabe
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Kinoshita
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Itoh
authors.forename: Kenichi
authors.initials: K
authors.lastname: Yoshimura
authors.forename: Michinori
authors.initials: M
authors.lastname: Ogura
authors.forename: Yoshitoyo
authors.initials: Y
authors.lastname: Kagami
authors.forename: Motoko
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: Mitsutoshi
authors.initials: M
authors.lastname: Kurosawa
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Tsukasaki
authors.forename: Masaharu
authors.initials: M
authors.lastname: Kasai
authors.forename: Kensei
authors.initials: K
authors.lastname: Tobinai
authors.forename: Harumi
authors.initials: H
authors.lastname: Kaba
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Mukai
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakamura
authors.forename: Koichi
authors.initials: K
authors.lastname: Ohshima
authors.forename: Tomomitsu
authors.initials: T
authors.lastname: Hotta
authors.forename: Masanori
authors.initials: M
authors.lastname: Shimoyama
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D001798:Blood Proteins / Q000378:metabolism*; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects / Q000473:pathology; D054391:Lymphoma, Extranodal NK-T-Cell / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D016411:Lymphoma, T-Cell, Peripheral / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D001798:Blood Proteins